| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cancer burden in adolescents and young adults in Europe
|
Trama, A.
|
|
|
8 |
1 |
p.
|
artikel
|
| 2 |
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial ☆
|
de Azambuja, E.
|
|
|
8 |
1 |
p.
|
artikel
|
| 3 |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions
|
Castelo-Branco, L.
|
|
|
8 |
1 |
p.
|
artikel
|
| 4 |
Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort
|
Pomej, K.
|
|
|
8 |
1 |
p.
|
artikel
|
| 5 |
Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
|
Kubota, Y.
|
|
|
8 |
1 |
p.
|
artikel
|
| 6 |
Design, power, and alpha levels in randomized phase II oncology trials
|
Haslam, A.
|
|
|
8 |
1 |
p.
|
artikel
|
| 7 |
Development and validation of a risk score (Delay-7) to predict the occurrence of a treatment delay following cycle 1 chemotherapy
|
Chambers, P.
|
|
|
8 |
1 |
p.
|
artikel
|
| 8 |
Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials
|
Uson Junior, P.L.S.
|
|
|
8 |
1 |
p.
|
artikel
|
| 9 |
Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
|
Raoul, J.L.
|
|
|
8 |
1 |
p.
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
8 |
1 |
p.
|
artikel
|
| 11 |
Emerging targets for cancer treatment: S100A9/RAGE
|
Valiente, M.
|
|
|
8 |
1 |
p.
|
artikel
|
| 12 |
FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty
|
Platt, J.R.
|
|
|
8 |
1 |
p.
|
artikel
|
| 13 |
Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists
|
Büttelmann, M.
|
|
|
8 |
1 |
p.
|
artikel
|
| 14 |
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
|
Reni, M.
|
|
|
8 |
1 |
p.
|
artikel
|
| 15 |
How I treat diffuse large B-cell lymphoma
|
Melchardt, T.
|
|
|
8 |
1 |
p.
|
artikel
|
| 16 |
How we treat esophageal squamous cell carcinoma
|
Puhr, H.C.
|
|
|
8 |
1 |
p.
|
artikel
|
| 17 |
Impact of EGFR A289T/V mutation on relapse pattern in glioblastoma
|
Noeuveglise, A.
|
|
|
8 |
1 |
p.
|
artikel
|
| 18 |
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
|
Paulsen, N.H.
|
|
|
8 |
1 |
p.
|
artikel
|
| 19 |
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
|
Gampenrieder, S.P.
|
|
|
8 |
1 |
p.
|
artikel
|
| 20 |
In the Literature: January 2023
|
Martín-Arana, J.
|
|
|
8 |
1 |
p.
|
artikel
|
| 21 |
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy
|
Fendl, B.
|
|
|
8 |
1 |
p.
|
artikel
|
| 22 |
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature
|
Boutros, A.
|
|
|
8 |
1 |
p.
|
artikel
|
| 23 |
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs
|
Overbeek, J.K.
|
|
|
8 |
1 |
p.
|
artikel
|
| 24 |
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines
|
Zarkavelis, G.
|
|
|
8 |
1 |
p.
|
artikel
|
| 25 |
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
|
van der Veldt, A.A.M.
|
|
|
8 |
1 |
p.
|
artikel
|
| 26 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
|
Koppikar, S.
|
|
|
8 |
1 |
p.
|
artikel
|
| 27 |
Precision medicine in early breast cancer—beginning of a successful story?
|
Eniu, A.
|
|
|
8 |
1 |
p.
|
artikel
|
| 28 |
Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases
|
Woldmar, N.
|
|
|
8 |
1 |
p.
|
artikel
|
| 29 |
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study
|
Cardone, C.
|
|
|
8 |
1 |
p.
|
artikel
|
| 30 |
Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure
|
Feldman, E.
|
|
|
8 |
1 |
p.
|
artikel
|
| 31 |
Table of Contents
|
|
|
|
8 |
1 |
p.
|
artikel
|
| 32 |
Targeting HER3 for cancer treatment: a new horizon for an old target
|
Uliano, J.
|
|
|
8 |
1 |
p.
|
artikel
|
| 33 |
Targeting KRASG12C in colorectal cancer: the beginning of a new era
|
Ciardiello, D.
|
|
|
8 |
1 |
p.
|
artikel
|
| 34 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
|
Su, Y.-Y.
|
|
|
8 |
1 |
p.
|
artikel
|
| 35 |
The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
|
Buijs, S.M.
|
|
|
8 |
1 |
p.
|
artikel
|
| 36 |
Twelve ESMO Congress 2022 breakthroughs: practicing oncologists’ perceptions and potential application on presented data
|
van Halteren, H.K.
|
|
|
8 |
1 |
p.
|
artikel
|
Tijdschrift beschrijving